Polmacoxib Pregabalin Double-Layered Tablet Pain Management
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pain management treatments for acute and chronic pain, particularly those involving inflammation and neuropathy, often require multiple medications and have stability issues due to external factors, leading to suboptimal efficacy and convenience.
Innovation Solution
A pharmaceutical composition combining polmacoxib and pregabalin in a single dosage form, with varying weight ratios and formulations such as tablets or suspensions, including a double-layered or multi-layered structure for sustained and immediate release, using pharmaceutically acceptable excipients and carriers to enhance stability and bioavailability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If multiple medications are used for pain management, then treatment coverage is improved, but treatment complexity and patient burden increase
Solution Approach 1:
The patent combines two distinct analgesic mechanisms (COX-2 inhibition by polmacoxib and calcium channel modulation by pregabalin) into a single fixed-dose tablet formulation. This merging approach maintains comprehensive treatment coverage for inflammatory and neuropathic pain components while reducing pill burden and simplifying the treatment regimen for patients
2Ease of operation
If medications are combined in a single dosage form, then convenience is improved, but drug stability and interaction control become more difficult
Solution Approach 1:
The tablet is divided into two distinct layers: an upper immediate-release layer containing polmacoxib and a lower sustained-release layer containing pregabalin. This segmentation physically separates the two drugs within the single dosage form, preventing direct chemical interactions while maintaining convenient single-pill administration. The layer structure also allows independent optimization of stability conditions for each drug component
Solution Approach 2:
The patent employs specific excipients and coating materials as intermediaries between the two drug substances. These intermediary materials act as barriers that prevent direct contact between polmacoxib and pregabalin, thereby avoiding potential drug-drug interactions while still allowing both drugs to be delivered through a single formulation
3Duration of action of moving object
If sustained-release formulation is used, then duration of action is improved, but manufacturing complexity increases
Solution Approach 1:
The sustained-release mechanism is achieved through segmentation into two functional layers with different release profiles. The lower layer uses sustained-release excipients and a specific matrix structure to extend pregabalin release, while the upper layer provides immediate polmacoxib release. This segmented approach allows each layer to be optimized independently for its release characteristics
Solution Approach 2:
The tablet utilizes composite material structures with different excipients tailored to each drug's release requirements. The sustained-release layer incorporates polymers and matrix materials specifically selected to control pregabalin release kinetics, while the immediate-release layer uses excipients optimized for rapid polmacoxib dissolution. This composite material strategy enables differentiated release profiles within a single manufactured dosage form
Data Source
AI summary
The present invention relates to a composite agent comprising polmacoxib and pregabalin. The present invention relates to a pharmaceutical composition and a drug or pain reliever, which each comprise the two active ingredients of polmacoxib and pregabalin and, more particularly, to a drug or pain reliever for treatment of moderately severe, acute, chronic, or neuropathic pain attributed to inflammation and various factors, an effect thereof, and a use thereof.